异基因造血干细胞移植后复发防治新进展  

New progress in the prevention and treatment of relapse after allogeneic hematopoietic stem cell transplantation

作　　者：刘燕平 缪扣荣[1] LIU Yanping;MIAO Kourong(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Jian-gsu Province Hospital,Nanjing,210029,China)

机构地区：[1]南京医科大学第一附属医院,江苏省人民医院血液科,南京210029

出　　处：《临床血液学杂志》2023年第3期219-224,共6页Journal of Clinical Hematology

摘　　要：异基因造血干细胞移植在急性白血病的治疗地位越来越突出,是目前具有治愈可能的重要治疗手段,但移植后复发仍是目前导致移植失败的主要原因之一。移植后复发患者的预后极差,目前尚无统一的治疗方案,是临床上面临的重大难题。文章将从移植后复发的风险识别、预防及治疗3个方面对急性白血病患者移植后复发的防治新进展作一综述。Allogeneic hematopoietic stem cell transplantation(allo-HSCT),with a curative potential,has been playing a critical role in the treatment of acute leukemia.However,relapse after allo-HSCT is still one of the most common causes of the failure after transplantation.Patients who relapse after transplantation has poor prognosis and no standard treatment is available.Treatment of patients who relapse after allo-HSCT remains a challenge in clinical practice.We reviewed the current progress in the prevention and treatment of acute leukemia relapsed after allo-HSCT from three aspects,including the risk identification of post-transplant relapse,the prevention and treatment of relapse.

关 键 词：异基因造血干细胞移植 复发 预防 治疗 

分 类 号：R457.7[医药卫生—治疗学]